

BioGaia signs exclusive agreement in Sri Lanka

BioGaia has today signed an exclusive agreement with Axero Associates (Pvt) Limited for the rights to sell BioGaia ProTectis drops and tablets, BioGaia Gastrus and BioGaia ProDentis in Sri Lanka. The launch is planned to take place during early 2016.

Axero Associates (Pvt) Limited, is a rapidly growing pharmaceutical company in Sri Lanka. The company's business consists of licensing, business development, marketing, sales and distribution of a wide range of products, both over-the-counter and prescription drugs, in many different therapeutic segments. Axero markets its products towards health care professionals through a team of medical delegates.

Axero will initially launch BioGaia ProTectis drops and tablets, BioGaia's biggest products, and later also market BioGaia ProDentis and Gastrus. Today the drops are sold in 70 countries and the tablets in 50 countries worldwide.

"We see a great potential for BioGaia's probiotics in Sri Lanka and look forward to bringing these well documented products to our market and to a successful cooperation with BioGaia", says Kapila Dayaratne, Managing Director, Axero.

Sri Lanka has 20 million inhabitants and a per capita income of USD 3,200. The economy is set to grow at a rapid pace of 7 to 8 per cent in the next few years with an increase in purchasing power per capita.

"Asia is a market with great potential and I am pleased that BioGaia's products will be available in yet another country here. With the reputable local partner Axero we hope for a successful launch of our key products in Sri Lanka", says Peter Rothschild, President, BioGaia.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2015-10-20	BioGaia appoints new Managing Director
2015-10-12	BioGaia's probiotic shown to promote growth and prevent recurrent diarrhoea
2015-09-07	BioGaia to invest further in Infant Bacterial Therapeutics AB

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com